Navigation Links
Perrigo Reports Record Third Quarter
Date:5/7/2009

payment of $8.5 million. The decrease in net sales was also due to an $8.2 million reduction in non-product revenue, as well as pricing pressures due to continued competition in the marketplace for generic drugs. These decreases were partially offset by new product sales of approximately $11.0 million, along with an increase in sales volumes on the Company's existing portfolio of products of approximately $7.0 million.

On March 17, 2009, the Company announced that its partner Cobrek Pharmaceuticals, Inc. (Cobrek) had filed an Abbreviated New Drug Application (ANDA) for Clindamycin Phosphate Foam 1%, a generic version of Evoclin(R) Foam 1%. The Company believes that Cobrek is the first to file an ANDA with a Paragraph IV certification against Evoclin(R). Evoclin(R) (clindamycin phosphate) Foam 1% is a topical antibiotic indicated for topical application in the treatment of acne vulgaris, and had sales of approximately $44 million for the 12 months ended January 2009, as measured by Wolters Kluwer Health.

API

The API segment reported third quarter net sales of $31.0 million compared with $37.8 million a year ago. The decrease was due primarily to the absence of a one-time $4.9 million accrual reversal related to a long standing customer contract negotiation recognized in fiscal 2008, along with approximately $2.0 million resulting from unfavorable changes in foreign currency exchange rates. Operating income was $4.3 million, compared with $6.0 million last year, reflecting the aforementioned accrual reversal, as well as unfavorable foreign currency exchange rate changes, partially offset by favorable contributions from new products, pricing improvements and lower operating expenses.

For the first nine months of fiscal year 2009, net sales decreased 13% compared to fiscal 2008. This decrease was due primarily to a decline of approximately $16.7 million in sales of three key products, the abse
'/>"/>

SOURCE Perrigo Company
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22

Related medicine news :

1. Perrigo Vice Chair Mori Arkin To Retire After 30 Years of Service
2. Perrigo Company to Host Analyst Meeting on September 18, 2007
3. Perrigo Company Announces FDA Approval for Ciclopirox Topical Solution
4. Perrigo Company Announces FDA Approval for Ciclopirox Topical Solution
5. Perrigo Confirms Filing for Generic Version of Mucinex(R) and Announcement of Lawsuit by Adams Respiratory
6. Perrigo Company Will Release First Quarter Fiscal 2008 Results on November 1, 2007
7. Perrigo Company Announces Dividend Increase
8. Perrigo Announces that Dexcels Settlement with AstraZeneca Allows OTC Omeprazole Launch Following Final FDA Approval
9. Perrigo Company to Present at The 26th Annual JPMorgan Healthcare Conference
10. Perrigo Acquires UK OTC Store Brand Supplier
11. Perrigo Company Authorizes Continuation of Share Repurchase Program and Announces Quarterly Dividend
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... (PRWEB) September 18, 2014 It is almost ... sprint or walk for healthier and happier kids. The ... participate in the 4th Annual Miami Children’s Hospital 5K Run/Walk. ... http://www.hyundaihopeonwheels.org , The 5K will take place ... will be outside of Coral Gables City Hall located at ...
(Date:9/18/2014)... (PRWEB) September 18, 2014 Clinical trial ... data on the Edema clinical trial scenario. This report ... trials on Edema. It includes an overview of the ... site of trial conduction across the globe. The databook ... their phase, trial status, prominence of the sponsors and ...
(Date:9/18/2014)... PA (PRWEB) September 18, 2014 ... announces the launch of Good Neighbor Pharmacy University, ... access information that will educate and empower pharmacy ... “As the healthcare industry continues to evolve, Good ... as we deliver resources and tools to help ...
(Date:9/18/2014)... September 18, 2014 CD-adapco, the largest ... software, today announced its new partnership with Ben Ainslie ... CD-adapco simulation tool, STAR-CCM+® in the design of its ... participation in the 35th America’s Cup taking place in ... the America’s Cup is sustainability, the set of restrictive ...
(Date:9/18/2014)... more vegetables and drink less sugar, according to a ... it,s still not enough, the study goes on to ... comes to eating healthier at school , The research ... status, may inform a child,s diet. , The study ... education were 85 per cent more likely to eat ...
Breaking Medicine News(10 mins):Health News:South Florida Hyundai Dealers Association Proudly Support the 4th Annual Miami Children’s Hospital 5K Run/Walk this Saturday August 20th in Coral Gables 2Health News:South Florida Hyundai Dealers Association Proudly Support the 4th Annual Miami Children’s Hospital 5K Run/Walk this Saturday August 20th in Coral Gables 3Health News:Edema Therapeutics Clinical Trials Market 2014 Review Report Available at MarketOptimizer.org 2Health News:Edema Therapeutics Clinical Trials Market 2014 Review Report Available at MarketOptimizer.org 3Health News:Edema Therapeutics Clinical Trials Market 2014 Review Report Available at MarketOptimizer.org 4Health News:Good Neighbor Pharmacy University Keeps Pharmacists Ahead of the Curve 2Health News:Ben Ainslie Racing Using STAR-CCM+ Simulation Software to Design 35th America’s Cup Racing Boat 2Health News:Kids eat better if their parents went to college 2
... Hundreds ... HCG and how can it help us? , ... May 13, 2010 -- HCG, or human chorionic gonadotropin, is a natural hormone that is found in ... as energy for both the mom and her developing baby. , , , , ,Now, thanks ...
... ... cut from the USDA-NIFA budget, causing a concern among scientists about how urgent, near-term challenges ... (PRWEB) ... appeal to the U.S. Department of Agriculture (USDA) National Institute of Food and Agriculture (NIFA) ...
... ... InterHealth Canada,s three new Turks and Caicos clinical facilities allowing the islands to provide ... ... Telemedicine Inc, the worldwide leading supplier of telemedicine technology , devices, and application ...
... an increased risk of blindness, yet nearly half of the ... annual eye exam to detect possible problems. But ... problems related to diabetes can help meet the screening need, ... compared the ability of two sets of computer programs to ...
... ... House Appropriations Subcommittee to increase funding to federal programs supporting Meharry and the nation,s ... ... M.D., MPH, MBA, MACP, President & Chief Executive Officer of Meharry Medical ...
... can cause trouble, experts say , WEDNESDAY, May 12 (HealthDay ... implant and maintain could make life better for people who ... , A defibrillator delivers an electric shock to restart a ... implanted in Americans each year. Current models require careful surgery ...
Cached Medicine News:Health News:All About the HCG Drops Diet Program—What it is and Why it Works 2Health News:WSSA Issues Strong Appeal to USDA for Restoration of Funding for Weed Science 2Health News:WSSA Issues Strong Appeal to USDA for Restoration of Funding for Weed Science 3Health News:WSSA Issues Strong Appeal to USDA for Restoration of Funding for Weed Science 4Health News:AMD Global Telemedicine Inc. Chosen by InterHealth Canada as the Telemedicine Solutions Provider for Turks and Caicos Hospital Project 2Health News:AMD Global Telemedicine Inc. Chosen by InterHealth Canada as the Telemedicine Solutions Provider for Turks and Caicos Hospital Project 3Health News:Computers can effectively detect diabetes-related eye problems 2Health News:Computers can effectively detect diabetes-related eye problems 3Health News:Meharry Medical College President Testifies Before the U.S. House of Representatives 2Health News:Meharry Medical College President Testifies Before the U.S. House of Representatives 3Health News:New Implanted Defibrillator May Be Simpler, Safer 2Health News:New Implanted Defibrillator May Be Simpler, Safer 3
(Date:9/18/2014)... , Sept. 18, 2014 MiMedx Group, ... developer, processor and marketer of patent protected regenerative ... announced today that it has entered into a ... MiMedx will provide its dehydrated human amnion/chorion membrane ... non- exclusively on a private label basis. ...
(Date:9/18/2014)... 18, 2014  Halozyme Therapeutics, Inc. (NASDAQ: ... Food and Drug Administration (FDA) has removed the ... PEGPH20 in SWOG,s ongoing Phase 1b/2 clinical trial ... investigational drug PEGPH20 (PEGylated Recombinant Human Hyaluronidase) in ... with metastatic pancreatic adenocarcinoma.  The study will resume ...
(Date:9/18/2014)... -- Relmada Therapeutics, Inc., (OTCQB: RLMD), a clinical-stage company ... announced today that it has appointed Mr. Christopher ... of Clinical Development. During his extensive career ... successful global clinical operations teams, in the US and ... development of numerous therapeutics and diagnostics across a broad ...
Breaking Medicine Technology:MiMedx Signs Distribution Agreement With Zimmer 2MiMedx Signs Distribution Agreement With Zimmer 3SWOG To Resume Clinical Trial Of Halozyme's PEGPH20 In Combination With Modified FOLFIRINOX For Advanced Pancreatic Cancer 2SWOG To Resume Clinical Trial Of Halozyme's PEGPH20 In Combination With Modified FOLFIRINOX For Advanced Pancreatic Cancer 3SWOG To Resume Clinical Trial Of Halozyme's PEGPH20 In Combination With Modified FOLFIRINOX For Advanced Pancreatic Cancer 4Relmada Therapeutics, Inc. Appoints Christopher W. James As Senior Director of Clinical Development 2
... (ASX: PGL; Nasdaq: PGLA) today announced additional,data from the ... this,year. This data was presented at the 58th Annual ... Diseases in Boston, USA(1). As the Phase 2 ... data analysis described in this presentation was performed to,evaluate ...
... overall rate of sustained virologic response in ... long-acting interferons in ... Albuferon non-responder study presented at the, Annual Meeting of the American Association for the Study ... ...
Cached Medicine Technology:Progen Presents Additional Analysis of Data from PI-88 Phase 2 Liver Cancer Study at American Association for the Study of Liver Diseases 2Progen Presents Additional Analysis of Data from PI-88 Phase 2 Liver Cancer Study at American Association for the Study of Liver Diseases 3Human Genome Sciences Presents Results of Phase 2 Trial of Albuferon(R) in Chronic Hepatitis C Patients Who Failed To Respond To Previous Therapy 2Human Genome Sciences Presents Results of Phase 2 Trial of Albuferon(R) in Chronic Hepatitis C Patients Who Failed To Respond To Previous Therapy 3Human Genome Sciences Presents Results of Phase 2 Trial of Albuferon(R) in Chronic Hepatitis C Patients Who Failed To Respond To Previous Therapy 4Human Genome Sciences Presents Results of Phase 2 Trial of Albuferon(R) in Chronic Hepatitis C Patients Who Failed To Respond To Previous Therapy 5Human Genome Sciences Presents Results of Phase 2 Trial of Albuferon(R) in Chronic Hepatitis C Patients Who Failed To Respond To Previous Therapy 6
... German Craftsmanship have produced the ... world. Ocutek now makes them ... of the coveted Meisterbrief certificate, ... are qualified to become Ocutek ...
... Centuries of German Craftsmanship ... instrumentation in the world. Ocutek ... you! Only holders of the ... and eight-year apprenticeship, are qualified ...
Medtronic Ophthalmics offers a comprehensive selection of corneal trephine,blades and handles. Handcrafted, sharp, uniform blade edges promote a,symetrical and vertical cut of all corneal layers....
Medtronic Ophthalmics offers a comprehensive selection of corneal trephine,blades and handles. Handcrafted, sharp, uniform blade edges promote a,symetrical and vertical cut of all corneal layers....
Medicine Products: